sotatercept for PAH
Study Summary
This trial is testing a drug to see if it's safe and effective for treating Pulmonary Arterial Hypertension.
- PAH
- Pulmonary arterial hypertension
- Pulmonary Arterial Hypertension
Treatment Effectiveness
Effectiveness Progress
Study Objectives
10 Primary · 7 Secondary · Reporting Duration: From initiation of treatment Visit 1 to the end of study follow-up Visit 8 weeks after year 4
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
sotatercept
1 of 2
Sotatercept Treatment
1 of 2
Experimental Treatment
700 Total Participants · 2 Treatment Groups
Primary Treatment: sotatercept · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 14th, 2021
Last Reviewed: November 18th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.